Monday, April 6, 2020

Subscribers Only


What Does the Acetris Trade Agreements Act Decision Mean for Foreign Supply Chains?

March 10, 2020 @ 12:00 pm – 1:00 pm
Arnold & Porter

The Federal Circuit’s recent ruling in Acetris Health LLC v. United States, No. 18-2399 (Fed. Cir. 2020), held that pharmaceuticals with an active ingredient from India but manufactured into final form in the US qualify as “US made” for purposes of federal procurement law. The decision, if not successfully challenged, could have broad-ranging implications that extend beyond the pharmaceutical industry to any government contractor with international supply chains. Acetris also raises important questions about how federal agencies will implement the court’s guidance. Join us for a webinar focusing on what this new case may mean for your products and business processes.

Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.

Free Registration

Free access to Events Calendar, Job Postings, and Annual Review with 2 weeks free trial access to Newsletters